Some researches suggest that c-Abl is a treatment target for ALS, and it has been found that the c-Abl blocker dasatinib has neuroprotective effects against this disease in vitro and in vivo100. This evidence concerns the gene ABL1 and amyotrophic lateral sclerosis.